These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37556518)

  • 1. Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study.
    Klebanov N; Pahalyants V; Said JT; Murphy WS; Theodosakis N; Scarry J; Duey S; Klevens M; Lilly E; Semenov YR
    J Drugs Dermatol; 2023 Aug; 22(8):840-843. PubMed ID: 37556518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.
    Ferreira A; Oliveira-E-Silva A; Bettencourt P
    J Med Virol; 2021 Feb; 93(2):755-759. PubMed ID: 32644224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role for antimalarials in the management of COVID-19.
    Schrezenmeier EV; Burmester GR; Eckardt KU; Dörner T
    Curr Opin Rheumatol; 2020 Sep; 32(5):449-457. PubMed ID: 32675717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.
    Dragojevic Simic V; Miljkovic M; Stamenkovic D; Vekic B; Ratkovic N; Simic R; Rancic N
    Int J Clin Pract; 2021 Mar; 75(3):e13825. PubMed ID: 33156564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.
    Gasmi A; Peana M; Noor S; Lysiuk R; Menzel A; Gasmi Benahmed A; Bjørklund G
    Appl Microbiol Biotechnol; 2021 Feb; 105(4):1333-1343. PubMed ID: 33515285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
    Abella BS; Jolkovsky EL; Biney BT; Uspal JE; Hyman MC; Frank I; Hensley SE; Gill S; Vogl DT; Maillard I; Babushok DV; Huang AC; Nasta SD; Walsh JC; Wiletyo EP; Gimotty PA; Milone MC; Amaravadi RK;
    JAMA Intern Med; 2021 Feb; 181(2):195-202. PubMed ID: 33001138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
    Mehta S; Bhandari S; Mehta S
    J Glob Antimicrob Resist; 2020 Sep; 22():864-865. PubMed ID: 32777441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-Exposure Prophylaxis with Hydroxychloroquine Does Not Prevent COVID-19 nor Virus Related Venous Thromboembolism.
    Perrella A; Orlando V; Trama U; Bernardi FF; Menditto E; Coscioni E
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
    Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
    Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
    Nina PB; Dash AP
    Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimalarials as Antivirals for COVID-19: Believe it or Not!
    Saha BK; Bonnier A; Chong W
    Am J Med Sci; 2020 Dec; 360(6):618-630. PubMed ID: 32950177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
    Lentini G; Cavalluzzi MM; Habtemariam S
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32316270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
    Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
    Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020.
    Vivanco-Hidalgo RM; Molina I; Martinez E; Roman-Viñas R; Sánchez-Montalvá A; Fibla J; Pontes C; Velasco Muñoz C;
    Euro Surveill; 2021 Mar; 26(9):. PubMed ID: 33663646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?
    Moiseev S; Avdeev S; Brovko M; Novikov P; Fomin V
    Ann Rheum Dis; 2021 Feb; 80(2):e19. PubMed ID: 32317315
    [No Abstract]   [Full Text] [Related]  

  • 20. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
    Naghipour S; Ghodousi M; Rahsepar S; Elyasi S
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1119-1133. PubMed ID: 32631083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.